Aki Miyashita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aki Miyashita has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Hanako Funakoshi
Division of Infectious Diseases, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan
2 shared publicationsKeiko Nakamura
Department of Nursing, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan
2 shared publicationsMeiwa Shibata
Division of Infectious Diseases, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan
2 shared publicationsShigeko Miyokawa
Department of Nursing, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan
2 shared publicationsYuho Horikoshi
Division of Infectious Diseases, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan
2 shared publicationsAkira Watanabe
Medical Mycology Research Center, Chiba University, Chiba, Japan
1 shared publication
Latest Publications
- Open Access
- 7 February 2026
- Published by Elsevier in Infection Prevention in Practice
- Vol. 8 (2) , 100517
Impact of healthcare-associated respiratory virus infections in children
- 7 February 2026
- Published by Elsevier in Infection Prevention in Practice
- Vol. 8 (2) , 100517
Open AccessImpact of healthcare-associated respiratory virus infections in children
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70262
Duration of antibiotic therapy for pediatric ventilator‐associated pneumonia
Background: Although a seven‐day course of antibiotic therapy for ventilator‐associated pneumonia (VAP) is recommended for adult patients, the optimal duration in children remains unclear. Our study described the management of pediatric VAP by focusing on the treatment and clinical outcomes. Methods: We performed a retrospective cohort study in the Pediatric Intensive Care Unit (PICU) of a tertiary children's hospital. Children under 18 diagnosed with VAP between April 2016 and June 2023 were included. VAP was defined by the Centers for Disease Control and Prevention of the United States criteria. Exclusion criteria included co‐infections or a lack of prior antibiotic therapy. Demographic and microbiological data were collected from medical records. Results: Ninety patients were eligible for enrollment. The median age was 19 months (IQR: 10–69 months) and 44% were girls. The median pediatric index of mortality‐2 score was 4 (IQR: 1.3–8.6). Staphylococcus aureus was the most frequently isolated pathogen (28%), followed by Pseudomonas aeruginosa (22%). The median length of antibiotic therapy was six days (IQR: 6–7 days). Mortality on days 7 and 28 was 1% ( n = 1) and 6% ( n = 5), without VAP‐related deaths. The recurrence rate was 10% ( n = 9). The median ventilation‐free and PICU‐free days at day 28 were 22 and 17, respectively. Conclusion: Most patients received a six to seven‐day course of antibiotic therapy without adverse outcomes. The recurrence rate and the ventilation‐free and PICU‐free days were equivalent to or better than those reported previously for adults.
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70262
Duration of antibiotic therapy for pediatric ventilator‐associated pneumonia
Background: Although a seven‐day course of antibiotic therapy for ventilator‐associated pneumonia (VAP) is recommended for adult patients, the optimal duration in children remains unclear. Our study described the management of pediatric VAP by focusing on the treatment and clinical outcomes. Methods: We performed a retrospective cohort study in the Pediatric Intensive Care Unit (PICU) of a tertiary children's hospital. Children under 18 diagnosed with VAP between April 2016 and June 2023 were included. VAP was defined by the Centers for Disease Control and Prevention of the United States criteria. Exclusion criteria included co‐infections or a lack of prior antibiotic therapy. Demographic and microbiological data were collected from medical records. Results: Ninety patients were eligible for enrollment. The median age was 19 months (IQR: 10–69 months) and 44% were girls. The median pediatric index of mortality‐2 score was 4 (IQR: 1.3–8.6). Staphylococcus aureus was the most frequently isolated pathogen (28%), followed by Pseudomonas aeruginosa (22%). The median length of antibiotic therapy was six days (IQR: 6–7 days). Mortality on days 7 and 28 was 1% ( n = 1) and 6% ( n = 5), without VAP‐related deaths. The recurrence rate was 10% ( n = 9). The median ventilation‐free and PICU‐free days at day 28 were 22 and 17, respectively. Conclusion: Most patients received a six to seven‐day course of antibiotic therapy without adverse outcomes. The recurrence rate and the ventilation‐free and PICU‐free days were equivalent to or better than those reported previously for adults.
- 18 December 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (4) , e148-e149
First Report of Catheter-related Bloodstream Infection Caused by Filobasidium magnum
- 18 December 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (4) , e148-e149
First Report of Catheter-related Bloodstream Infection Caused by Filobasidium magnum